Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Montelukast blocks cysteinyl leukotrienes that drive antihistamine-resistant hives, reducing skin swelling and itch by limiting vascular leakage and immune cell activation. Clinical trials show adding montelukast to H1 antihistamines can cut hive counts by 30 to 50 percent, with most patients tolerating it well.
Several important considerations on dosing, monitoring, side effects and next steps exist, so see complete info below to guide your treatment plan.
Chronic hives (urticaria) cause itchy, red welts that can last for weeks or months. Most people find relief with H1 antihistamines, but a subset remains symptomatic despite high-dose or multiple antihistamines. In these antihistamine-resistant cases, adding leukotriene inhibitors montelukast for hives has shown promise. Below, we explore the immune science behind montelukast, review the evidence, and guide you on its safe use.
When antihistamines alone fail, it's often because inflammation involves more than just histamine. Leukotrienes—potent inflammatory mediators—play a key role in some patients.
What Are Leukotrienes?
Role in Hives
Because of this dual pathway, blocking histamine alone sometimes isn't enough. Leukotriene inhibitors montelukast for hives target this second pathway.
Montelukast is a selective antagonist of the cysteinyl leukotriene receptor (CysLT1). By blocking LTD4 and related leukotrienes, it:
This mechanism complements H1 antihistamines, offering a broader anti-inflammatory approach.
Several studies have assessed montelukast as an add-on for chronic urticaria:
While not everyone responds, montelukast's favorable side-effect profile and once-daily dosing make it an attractive option.
Consider leukotriene inhibitors montelukast for hives if you:
Always consult a healthcare professional before starting any new medication.
If symptoms improve, your doctor may continue montelukast long-term or taper based on severity.
Montelukast is generally well tolerated. Possible adverse effects include:
Important precautions:
A stepwise approach for antihistamine-resistant hives:
Confirm Adherence and Dosing
Optimize Antihistamine Therapy
Add Montelukast
Reassess Regularly
Escalate If Needed
Alongside medication, lifestyle modifications can help:
These habits complement pharmacotherapy and can reduce flare frequency.
Although chronic hives are rarely life threatening, certain signs warrant urgent care:
If you experience any of these, call emergency services and use an epinephrine auto-injector if prescribed.
For many with antihistamine-resistant chronic hives, adding leukotriene inhibitors montelukast for hives provides meaningful relief by targeting a second inflammatory pathway. While not a cure-all, montelukast's safety profile and convenience make it a valuable tool in the urticaria toolbox.
Remember to:
Speak to a doctor about your individual risks and benefits before starting montelukast or any new therapy, especially if symptoms are severe or life threatening.
(References)
* Gupta S, Kumar B, Yadav S, Rai R, Singh SP. Role of leukotrienes in chronic urticaria and their therapeutic implications. Immunopharmacol Immunotoxicol. 2017 Jun;39(3):192-198. doi: 10.1080/08923973.2017.1293237. Epub 2017 Mar 7. PMID: 28264931.
* Godse KV, Godse GK. The role of leukotriene receptor antagonists in chronic urticaria. Clin Rev Allergy Immunol. 2008 Feb;34(1):50-3. doi: 10.1007/s12016-007-8025-x. PMID: 18029583.
* Bédard F, Barde C, Bédard D. Leukotriene receptor antagonists in chronic urticaria: systematic review. Ann Allergy Asthma Immunol. 2011 Oct;107(4):307-13.e1. doi: 10.1016/j.anai.2011.08.006. Epub 2011 Sep 22. PMID: 21976694.
* Min H, Zhang Q, Zhao Y. Mast cell-derived mediators in chronic spontaneous urticaria: from pathogenesis to treatment. Allergy Asthma Immunol Res. 2018 Jan;10(1):15-22. doi: 10.4168/aair.2018.10.1.15. Epub 2017 Oct 20. PMID: 29059639; PMCID: PMC5705353.
* Kolkhir P, Hawro T, Skov PS, Staubach P, Maurer M. Leukotriene receptor antagonists in chronic urticaria: A review of the evidence. Dermatol Ther. 2020 May;33(3):e13337. doi: 10.1111/dth.13337. Epub 2020 Feb 26. PMID: 32098675.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.